Fundz

Autoimmunity BioSolutions raised $2M in seed funding to advance their research in autoimmune treatments.

PRIVATENov 28, 2024

Amount Raised

$2 Million

Round Type

Seed

HoustonBiotechnology

Description

Autoimmunity BioSolutions has successfully completed a seed funding round, raising $2 million. The funds will be used to further their research and development of innovative treatments for autoimmune diseases.

Quick answer

Autoimmunity BioSolutions raised $2 Million in a Seed round, dated November 28, 2024. Autoimmunity BioSolutions is based in Houston, Texas, United States.

How much did Autoimmunity BioSolutions raise?
Autoimmunity BioSolutions raised $2 Million in a Seed round on November 28, 2024.
What does Autoimmunity BioSolutions do?
Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or "correct" elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor..
Where is Autoimmunity BioSolutions based and how big is it?
Autoimmunity BioSolutions is based in Houston, Texas, United States. Fundz records about 3 employees.
Who are the decision-makers at Autoimmunity BioSolutions?
Fundz holds 1 contact at Autoimmunity BioSolutions. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Autoimmunity BioSolutions that raised within 45 days of this round, from Fundz verified event records.

  • Windward Bio raised $200M (Series A) on January 10, 2025.
  • Light Horse Therapeutics raised $62M (Series A) on January 10, 2025.
  • Numab Therapeutics raised $55M (Series C) on January 10, 2025.
  • RhyGaze raised $86M (Series A) on January 10, 2025.
  • Kardigan raised $300M (Series A) on January 10, 2025.
  • Ouro Medicine raised $120M (Series A) on January 10, 2025.

Who to call at Autoimmunity BioSolutions, and when

A new round usually means Autoimmunity BioSolutions is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Autoimmunity BioSolutions raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Autoimmunity BioSolutions, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Autoimmunity BioSolutions. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Autoimmunity BioSolutions

Location

2710 REED RD, SUITE 160

Houston, Texas, United States

About

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or "correct" elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to treat numerous autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Autoimmunity BioSolutions raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Autoimmunity BioSolutions's next move

See what Strategic adds

Autoimmunity BioSolutions raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.